Sareum Holdings Plc (LON:SAR), the specialist cancer drug discovery and development company, has appointed Dr Stephen Parker as non-executive chairman of the company.
Dr Parker, chairman of Silence Therapeutics PLC, succeeds Dr Paul Harper with immediate effect.
Dr Parker's career in the healthcare and pharma sector spans over 30 years, including six years in the City in advisory roles.
Sareum's chief executive, Dr Tim Mitchell, thanked Paul Harper for his invaluable contribution to the company over the last 12 years.
“During his time with us Paul helped to define the direction and strategy of the company, which has allowed us build considerable value into our development programmes through their progression towards, and into, early clinical development,” Dr Mitchell said.
"We welcome Stephen to the board, who brings with him a wealth of financial and industry experience, which will be crucial to the business as we look towards the next stages of our transformation into a clinical-stage development company," he added.